Pharmaceutical Market Europe • April 2026 • 37
APPOINTMENTS
Mestag Therapeutics
Lindsey Rolfe and Pascal Merchiers
Mestag has appointed Lindsey Rolfe as Chief Medical Officer (CMO) and Pascal Merchiers as Chief Development Officer (CDO). Bringing over 30 years of clinical experience to the role, Rolfe was most recently the CMO of 3B Pharmaceuticals. Her other previous roles include CMO at Clovis Oncology and development roles at Celgene, Pharmion, Medimmune, UCB and Celltech.
Merchiers brings over 25 years of experience to Mestag, having most recently been CDO at Commit Biologics. During his career he has served as Chief Scientific Officer (CSO) at Aboleris and CSO at Oncurious.
Susan Hill, CEO of Mestag Therapeutics, said: “Lindsey’s extensive experience will be instrumental in shaping the advancement of our clinical programmes. Pascal’s breadth and depth of expertise in cancer and inflammatory disease will help drive our development activities.”
Helus Pharma
Jill Conwell
Helus Pharma, a clinical stage pharma company focused on developing novel serotonergic agonists (NSAs), has appointed Jill Conwell as Chief People Officer, effective immediately. Bringing over 20 years of leadership experience to the role, Conwell has previously held senior leadership roles at Aclaris Therapeutics, Idera Pharmaceuticals and Shire Pharmaceuticals.
Michael Cola, CEO of Helus Pharma, said: “Jill has a proven ability to help life sciences companies build and align teams, organisational strategies and processes to support ambitious growth.
RedSail Technologies
Joy Neely
RedSail Technologies has appointed Joy Neely as Chief Growth Officer. In her new role, Neely will lead the company’s commercial team, overseeing marketing, sales and market strategy, while working closely with the executive leadership team and other key stakeholders.
Neely was most recently Chief Commercial Officer at Medvantx. Prior to that, she was Senior VP and Head of Sale at CareMetx. Additionally, she was Market Access Development Leader at Roche and she also held a number of roles at Eli Lilly, where she spent over a decade.
Takeda
Julie Kim
Takeda has announced that Julie Kim, CEO-elect, is to be proposed as a candidate for the Board of Directors and Representative Director, President and CEO. If elected, Julie Kim will assume these new roles immediately after the meeting in June, with Christophe Weber, who is currently in the role, planning to retire from Takeda on the same day. Other candidates for internal and external directors have also been proposed.
AEON Biopharma
John Bencich
AEON Biopharma has appointed John Bencich as CFO. Bringing more than 25 years of leadership experience to the role, Bencich previously served as CEO of Achieve Life Sciences where he led the company’s capitalisation. Earlier in his career, Bencich held CFO positions at OncoGenex Pharmaceuticals, Integrated Diagnostics, Allozyne and Trubion Pharmaceuticals, where he supported multiple financings and strategic transactions.
Odyssey Therapeutics
H. Martin Seidel
Odyssey Therapeutics has appointed H. Martin Seidel to its Scientific Advisory Board. Seidel is currently CEO of IFM Therapeutics. Previously, Seidel spent over a decade at Novartis Institutes for Biomedical Research in senior leadership roles, including Head of the Genomics Institute of the Novartis Research Foundation and Global Head of Business Development & Licensing, overseeing scientific collaborations and strategic transactions.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services